Ann: Investor Update , page-7

It's good to see the advantages of this deal spelled out by the management. Adds some credibility to the discussions on this forum.


from the announcement....
'Compared to a traditional healthcare licensing agreement, the combination of the above
partnerships will optimise the requisite skill sets and provide a number of commercially
important advantages to Tissue Therapies including:
• Tissue Therapies will retain control of launch plans, messaging, promotions,
literature, advertising, sampling and individual country launches.
• Tissue Therapies will retain a higher % of net income.
• The sales staff will be focused exclusively on Tissue Therapies and selling
VitroGro® ECM. They will not be selling a large portfolio of products of which
VitroGro® ECM will be only one.
• The potential threats to VitroGro® ECM sales of a large partner’s competing internal
corporate strategies and changing priorities are avoided.
• Tissue Therapies retains complete flexibility to enter into other commercial
arrangements for global sales of VitroGro® ECM in the EU and globally.